Cutaneous Oncology and Immunomodulator Therapy : From Warts to Skin Cancers

James,M.,Spencer,Q.,D. Rosso,Douglas,W.,Kress

Abstract:

What problem does this paper attempt to address?

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Alberto J Espay,Fabrizio Stocchi,Rajesh Pahwa,Alberto Albanese,Aaron Ellenbogen,Joaquim J Ferreira,Nir Giladi,Tanya Gurevich,Sharon Hassin-Baer,Jorge Hernandez-Vara,Stuart H Isaacson,Karl Kieburtz,Peter A LeWitt,Lydia Lopez-Manzanares,C Warren Olanow,Werner Poewe,Harini Sarva,Tami Yardeni,Liat Adar,Laurence Salin,Nelson Lopes,Nissim Sasson,Ryan Case,Olivier Rascol,BouNDless Study Group,Mitra Afshari,Alexander Amelin,David Arkadir,Samih Badarny,Ernest Balaguer Martinez,Andrzej Bogucki,James Boyd,Laura Buyan Dent,Camille Carroll,Kallol Ray Chaudhuri,Jeffrey Cooney,Anne-Gaëlle Corbillé,Teodor Danaila,Maria Francesca De Pandis,Sophie Dethy,Rohit Dhall,Ruth Djaldetti,Franck Durif,Stephen Flitman,Eric Freire Alvarez,John Goudreau,Francisco Grandas Perez,Tanya Gurevich,Arnaldo Isa,Jorge L Juncos,Sulada Kanchana,Gabriela Klodowska-Duda,Dariusz Koziorowski,Jaime Kulisevsky Bojarski,Juan Lopez Lozano,Lan Luo,Nataliya Lytvynenko,Roberto Marconi,Ana-Raquel Marques,Juan Carlos Martinez Castrillo,Irene Martinez Torres,Aashoo Mentreddi,Pablo Mir Rivera,Sergii Moskovko,Yuliya Neryanova,Marco Onofrj,Jill Ostrem,Claudio Pacchetti,Nicola Pavese,Clelia Pellicano,Gonzalo Revuelta,Ana Margarida Rodrigues,Ramon Rodriguez,Monika Rudzinska,Nighat Sarwar,Julie Schwartzbard,Laura Scorr,John Slevin,Tatyana Slobodin,Gianfranco Spalletta,Michele Tagliati,Yen Tai,Alessandro Tessitore,Peter Valkovic,Leo Verhagen,Elena Vostrikova,Gilad Yahalom,Zuleykha Zalyalova,Katerina Zarubova,Irina Zhukova

DOI: https://doi.org/10.1016/s1474-4422(24)00052-8

IF: 59.935

2024-03-01

The Lancet Neurology

Abstract:BACKGROUND: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-release levodopa-carbidopa for the treatment of motor fluctuations in people with Parkinson's disease.METHODS: We conducted a phase 3, randomised, double-blind, double-dummy, active-controlled, multicentre trial at 117 academic and community neurology sites in 16 countries, including in Europe, Israel, and the USA. Eligible participants were men and women aged 30 years or older with a diagnosis of Parkinson's disease (Hoehn and Yahr stage ≤3 in the on state) who experienced at least 2·5 h/day of off time. Participants underwent an open-label run-in phase (<12 weeks), during which time optimal regimens were established for both oral immediate-release levodopa-carbidopa and for 24 h/day subcutaneous ND0612 infusion (levodopa-carbidopa 60·0/7·5 mg/mL), with supplemental oral levodopa-carbidopa if needed. Participants were then randomly assigned (1:1) to 12 weeks of double-blind treatment with their optimised regimen of either subcutaneous ND0612 or oral levodopa-carbidopa, with matching oral or subcutaneous placebo given as required to maintain blinding. Randomisation was done via an interactive web response system, stratified by region, using a permuted block schedule. Participants, study partners, treating investigators, study site personnel, and the sponsor were masked to treatment group allocation. The primary efficacy endpoint was the change from baseline (ie, time of randomisation, when all patients were receiving an optimised open-label ND0612 regimen) to end of the double-blind phase in total daily on time without troublesome dyskinesia, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, NCT04006210, and is complete.FINDINGS: Between Sept 30, 2019, and April 8, 2022, 381 participants were enrolled, of whom 259 (68%) were randomly assigned, 128 (49%) to subcutaneous ND0612 and 131 (51%) to oral levodopa-carbidopa. 243 (94%) participants completed the study. Treatment with subcutaneous ND0612 provided an additional 1·72 h (95% CI 1·08 to 2·36) of on time without troublesome dyskinesia compared with oral levodopa-carbidopa (change from baseline of -0·48 h [-0·94 to -0·02] with subcutaneous ND0612 vs -2·20 h [-2·65 to -1·74] with oral levodopa-carbidopa; p<0·0001). Significant treatment differences favouring subcutaneous ND0612 were also found in the first four of nine prespecified hierarchical outcomes of daily off time (-1·40 h [95% CI -1·99 to -0·80]), Movement Disorders Society-Unified Parkinson's Disease Rating Scale part II scores (-3·05 [-4·28 to -1·81]), Patients Global Impression of Change (odds ratio [OR] 5·31 [2·67 to 10·58]), and Clinical Global Impression of Improvement (OR 7·23 [3·57 to 14·64]). Hierarchical testing ended after the fourth secondary endpoint. Adverse events were reported by 287 (89%) of 322 participants during open-label ND0612 optimisation, and by 103 (80%) of 128 in the ND0612 group and 97 (74%) of 131 in the oral levodopa-carbidopa group during the double-blind phase. The most common adverse events were infusion-site reactions (266 [83%] participants during open-label ND0612, and 73 [57%] in the ND0612 group vs 56 [43%] in the oral levodopa-carbidopa group during the double-blind phase), most of which were mild. Serious adverse events in four participants in the ND0612 group were related to study treatment (infusion-site cellulitis [n=2], infusion-site abscess and infusion-site ulcer [n=1]; and paraesthesia and peripheral sensorimotor neuropathy [n=1]). One participant in the ND0612 group died during the double-blind phase, but the death was not related to study treatment (fall leading to traumatic brain injury).INTERPRETATION: Results of this phase 3 study showed that subcutaneous ND0612 used in combination with oral immediate-release levodopa-carbidopa increased on time without troublesome dyskinesia and reduced off time, with a favourable benefit-risk profile. ND0612 might offer a safe and efficacious subcutaneous levodopa infusion approach to managing motor fluctuations in people with Parkinson's disease. The ongoing open-label extension phase will provide further information on the long-term efficacy and safety of treatment.FUNDING: NeuroDerm.

clinical neurology
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

Victor S.C. Fung,Jason Aldred,Martha P. Arroyo,Filip Bergquist,Agnita J.W. Boon,Manon Bouchard,Sarah Bray,Sara Dhanani,Maurizio F. Facheris,Nahome Fisseha,Eric Freire-Alvarez,Robert A. Hauser,Anna Jeong,Jia Jia,Pavnit Kukreja,Michael J. Soileau,Amy M. Spiegel,Saritha Talapala,Arjun Tarakad,Enrique Urrea-Mendoza,Jorge Zamudio,Rajesh Pahwa

DOI: https://doi.org/10.1016/j.prdoa.2024.100239

2024-01-01

Clinical Parkinsonism & Related Disorders

Abstract:Background: As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady dopaminergic stimulation that can reduce symptom fluctuation.Objective: Our aim is to review the initiation, optimization, and maintenance of LDp/CDp therapy, identify possible challenges, and share potential mitigations.Methods: Review available LDp/CDp clinical trial data for practical considerations regarding the management of patients during LDp/CDp therapy initiation, optimization, and maintenance based on investigator clinical trial experience.Results: LDp/CDp initiation, optimization, and maintenance can be done without hospitalization in the clinic setting. Continuous 24 h/day LDp/CDp infusion can offer more precise symptom control than oral medications, showing improvements in motor fluctuations during both daytime and nighttime hours. Challenges include infusion-site adverse events for which early detection and prompt management may be required, as well as systemic adverse events (eg, hallucinations) that may require adjustment of the infusion rate or other interventions. A learning curve should be anticipated with initiation of therapy, and expectation setting with patients and care partners is key to successful initiation and maintenance of therapy.Conclusion: Continuous subcutaneous infusion of LDp/CDp represents a promising therapeutic option for individuals with PD. Individualized dose optimization during both daytime and nighttime hours, coupled with patient education, and early recognition of certain adverse events (plus their appropriate management) are required for the success of this minimally invasive and highly efficacious therapy.

English Else
Subcutaneous Levodopa: A New Engine for the Vintage Molecule

Karolina Poplawska-Domaszewicz,Lucia Batzu,Cristian Falup-Pecurariu,K. Ray Chaudhuri

DOI: https://doi.org/10.1007/s40120-024-00635-4

2024-06-16

Neurology and Therapy

Abstract:The management of Parkinson's disease (PD) continues to evolve with advancements in non-oral levodopa-based therapies aiming to provide continuous drug delivery (CDD). Such therapies address the challenges posed by the emergence of motor fluctuations, dyskinesias, and non-motor fluctuations (NMF) associated with oral levodopa administration and contributing to define the advanced stage of PD. The key focus of this review is placed on subcutaneous foslevodopa/foscarbidopa (Foslevodopa/foscarbidopa) infusion, showcasing its recent clinical availability and efficacy in providing continuous levodopa delivery. While providing an overview of the other non-oral levodopa-based CDD systems, such as intrajejunal levodopa–carbidopa infusion and levodopa–entacapone–carbidopa infusion, we highlight the current promising evidence for Foslevodopa/foscarbidopa to improve, for example, "on time" without troublesome dyskinesia and reducing "off time" in people with advanced PD. Additionally, Foslevodopa/foscarbidopa demonstrates potential in managing early morning off periods, sleep quality and other motor and non-motor symptoms. Moreover, other non-oral CDD options such as ND0612 and DIZ102/DIZ101 are discussed, with focus on their pharmacokinetics/pharmacodynamics, efficacy, and safety profiles. While these advancements present new therapeutic avenues, long-term observational studies are warranted to elucidate their impact on existing PD therapies. Overall, this review provides insights into the evolving landscape of non-oral CDD therapies and offers a pragmatic approach for their integration into clinical practice.

clinical neurology
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

Jan Kassubek,Stewart A. Factor,Ernest Balaguer,Johannes Schwarz,K. Ray Chaudhuri,Stuart H. Isaacson,Stacy Wu,Carmen Denecke Muhr,Jaime Kulisevsky

DOI: https://doi.org/10.1007/s00415-024-12323-2

2024-03-28

Journal of Neurology

Abstract:Abstract Background Apomorphine sublingual film (SL-APO) is an on-demand treatment for OFF episodes in patients with Parkinson’s disease (PD). Objective To assess the long-term (≥ 3 years) safety/tolerability and efficacy of SL-APO. Methods Study CTH-301 ( http://www.clinicaltrials.gov NCT02542696; registered 2015-09-03) was a phase 3, multicentre, open-label study of SL-APO in PD patients with motor fluctuations, comprised of a dose-titration and long-term safety phase. All participants received SL-APO. The primary endpoint was safety/tolerability (treatment-emergent adverse events [TEAEs]) during the long-term safety phase. Efficacy assessments included the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III (motor examination), assessed at weeks 24, 36 and 48 during the first year of the long-term safety phase. Results 496 patients were included and 120 (24.2%) completed the long-term safety phase. Mean duration of SL-APO exposure was 294.3 days. TEAEs related to study drug were experienced by 65.3% of patients (most common: nausea [6.0%], stomatitis [1.8%], lip swelling [1.8%], dizziness [1.6%], oral mucosal erythema [1.6%], mouth ulceration [1.6%]). TEAEs leading to study drug withdrawal were experienced by 34.0% of patients (most common: nausea [5.4%], lip swelling [4.5%], mouth ulceration [2.6%], stomatitis [2.3%]). A clinically meaningful reduction in MDS-UPDRS part III score was observed as soon as 15 min following administration of SL-APO, with peak effects observed approximately 30 min post-dose and sustained up to 90 min post-dose; results were consistent over 48 weeks. Conclusions SL-APO was generally well tolerated and efficacious over the long term as an on-demand treatment for OFF episodes in patients with PD.

clinical neurology
DFT description of the magnetic properties and electron localization in dinuclear di-mu-oxo-bridged manganese complexes.

V. Barone,A. Bencini,D. Gatteschi,F. Totti

DOI: https://doi.org/10.1002/1521-3765(20021104)8:21<5019::AID-CHEM5019>3.0.CO;2-Y

2002-11-04

Chemistry

Abstract:Density functional theory (DFT) was applied to describe the magnetic and electron-transfer properties of dinuclear systems containing the [MnO2Mn]n+ core, with n=0,1,2,3,4. The calculation of the potential energy surfaces (PESs) of the mixed-valence species (n=1,3) allowed the classification of these systems according to the extent of valence localization as Class II compounds, in the Robin-Day classification scheme. The fundamental frequencies corresponding to the asymmetric breathing vibration were also computed.
Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease

B. Post,B. Bloem,T. van Laar,C. V. Verschuur,G. Tissingh,A. Munts,A. Lang,R. D. de Haan,R. D. de Bie,J. Boel,S. Suwijn,J. V. van Hilten,G. Deuschl,M. Dijkgraaf

DOI: https://doi.org/10.1056/NEJMoa1809983

IF: 158.5

2019-01-24

New England Journal of Medicine

Abstract:BACKGROUND Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease‐modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated. METHODS In a multicenter, double‐blind, placebo‐controlled, delayed‐start trial, we randomly assigned patients with early Parkinson's disease to receive levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks (early‐start group) or placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks (delayed‐start group). The primary outcome was the between‐group difference in the mean change from baseline to week 80 in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS; scores range from 0 to 176, with higher scores signifying more severe disease). Secondary analyses included the progression of symptoms, as measured by the UPDRS score, between weeks 4 and 40 and the noninferiority of early initiation of treatment to delayed initiation between weeks 44 and 80, with a noninferiority margin of 0.055 points per week. RESULTS A total of 445 patients were randomly assigned: 222 to the early‐start group and 223 to the delayed‐start group. The mean (±SD) UPDRS score at baseline was 28.1±11.4 points in the early‐start group and 29.3±12.1 points in the delayed‐start group. The change in UPDRS score from baseline to week 80 was ‐1.0±13.1 points and ‐2.0±13.0 points, respectively (difference, 1.0 point; 95% confidence interval [CI], ‐1.5 to 3.5; P=0.44); this finding of no significant between‐group difference at week 80 implies that levodopa had no disease‐modifying effect. Between weeks 4 and 40, the rate of progression of symptoms, as measured in UPDRS points per week, was 0.04±0.23 in the early‐start group and 0.06±0.34 in the delayed‐start group (difference, ‐0.02; 95% CI, ‐0.07 to 0.03). The corresponding rates between weeks 44 and 80 were 0.10±0.25 and 0.03±0.28 (difference, 0.07; two‐sided 90% CI, 0.03 to 0.10); the difference in the rate of progression between weeks 44 and 80 did not meet the criterion for noninferiority of early receipt of levodopa to delayed receipt. The rates of dyskinesia and levodopa‐related fluctuations in motor response did not differ significantly between the two groups. CONCLUSIONS Among patients with early Parkinson's disease who were evaluated over the course of 80 weeks, treatment with levodopa in combination with carbidopa had no disease‐modifying effect. (Funded by the Netherlands Organization for Health Research and Development and others; LEAP Current Controlled Trials number, ISRCTN30518857.)

Medicine
Corrigendum to “the Efficacy and Safety of Ropinirole Prolonged Release Tablets As Adjunctive Therapy in Chinese Subjects with Advanced Parkinson’s Disease: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study” [parkinsonism and Related Disorders 19 (2013) 1022–1026]

Zhenxin Zhang,Jian Wang,Xiaoying Zhang,Shengdi Chen,Zhenfu Wang,Baorong Zhang,Chun‐Feng Liu,Qing Qu,Yan Cheng,Jie Li,Haijun Cao,Meiling Cai,Rongxuan Zhu

DOI: https://doi.org/10.1016/j.parkreldis.2014.03.025

2014-01-01

Abstract:The authors regret that errors have been found in Tables 1 and 2 and its corresponding paragraph within the text. The correct information is shown below, and the authors would like to apologise for any inconvenience caused. 3.2. Primary and secondary efficacy outcomes Hours of total awake time spent “off” were significantly decreased in the ropinirole PR group compared with placebo group (Table 2; Supplemental Figure 1). Hours of “on” time, “on” time without troublesome dyskinesia, were significantly increased, whereas the percent “off” time were significantly decreased for ropinirole PR compared with placebo (Table 2). For primary efficacy variables, similar results were observed for the PP population.Table 1Baseline demographic and clinical characteristics of subjects with Parkinson's disease (Safety population).aUnless noted otherwise, values are expressed as mean SD; PD: Parkinson's disease.Number of subjectsRopinirole PR (n = 175)Placebo (n = 170)Total (n = 345)Age (years)64.1 (9.0)63.6 (10.5)63.9 (9.7)Female, n (%)59 (33.7)65 (38.2)124 (35.9)Height (cm); mean [range]165.4 [145.0–183.0]165.1 [143.0–187.0]165.2 [143.0–187.0]Weight (kg); mean [range]63.9 [43.5–94.0]63.1 [40.0–97.0]63.5 [40.0–97.0]Duration of PD, months92.1 (59.9)95.7 (48.3)93.9 (54.4)Duration of L-dopa, months68.8 (49.2)69.7 (41.7)69.2 (45.6)L-dopa dose (mg/day)506.6 (290.9)539.8 (426.2)522.9 (363.6)Subjects with any concomitant medicines except for L-dopa during treatment period, n (%)153 (87.4)157 (92.4)31 (89.9)Amantadine hydrochloride71 (40.6)68 (40.0)139 (40.3)Selegiline hydrochloride31 (17.7)34 (20.0)65 (18.8)Trihexyphenidyl hydrochloride38 (21.7)24 (14.1)62 (18.0)Entacapone26 (14.9)27 (15.9)53 (15.4)a Unless noted otherwise, values are expressed as mean SD; PD: Parkinson's disease. Open table in a new tab Table 2Mean (SD) change from baseline in awake time spent “off”, awake time spent “on” and total awake time spent “on” without troublesome dyskinesia, UPDRS motor and ADL scores, HAMD-17 and PDSS scales and PDQ-39 domain scores at week 24 last observation carried forward (intention-to-treat population).BaselineWeek 24Change from BaselineAdjusted treatment difference 95% CIp-ValueRopinirole PR (N = 175)Placebo (N = 169)Ropinirole PR (N = 175)Placebo (N = 169)Ropinirole PR (N = 175)Placebo (N = 169)Total awake time spent ‘off’aA decrease from baseline indicates an improvement (h)7.0 (2.89)7.0 (2.90)4.9 (3.05)6.6 (3.25)−2.1 (2.58)−0.4 (2.47)−1.76 (−2.27, −1.26)<0.001Percent awake time spent ‘off’’aA decrease from baseline indicates an improvement45.4 (17.19)45.6 (17.03)31.9 (19.44)43.9 (20.17)−13.5 (15.62)−1.8 (15.88)−11.92 (−15.14, −8.70)<0.001Total awake time spent ‘on’bAn increase from baseline indicates an improvement. (h)8.4 (2.79)8.3 (2.71)10.4 (2.99)8.4 (3.05)1.9 (2.44)0.1 (2.48)1.90 (1.40, 2.40)<0.001Total awake time spent ‘on’ without troublesome dyskinesiabAn increase from baseline indicates an improvement. (h)7.9 (2.99)7.8 (2.90)9.6 (3.29)8.0 (3.28)1.7 (2.81)0.3 (2.56)1.49 (0.94, 2.03)<0.001UPDRS motoraA decrease from baseline indicates an improvement28.8 (13.35)29.3 (12.39)22.6 (12.17)28.6 (13.39)−6.3 (10.08)−0.7 (9.03)−5.66 (−7.53, −3.79)<0.001UPDRS ADLaA decrease from baseline indicates an improvement12.3 (5.81)13.2 (6.23)10.2 (5.16)13.1 (6.11)−2.2 (3.93)−0.2 (3.64)−2.25 (−2.99, −1.51)<0.001HAMD-17aA decrease from baseline indicates an improvement6.4 (4.76)7.9 (5.36)4.8 (4.30)7.3 (5.35)−1.6 (4.38)−0.6 (4.33)−1.66 (−2.48, −0.83)<0.001PDSS scale107.1 (23.25)103.3 (27.2)107.4 (24.52)102.1 (26.91)0.5 (21.22)−1.7 (20.57)3.26 (−0.94, 7.47)0.128PDQ-39 subscalecRopinirole PR n = 170 and placebo n = 160.MobilityaA decrease from baseline indicates an improvement33.9 (22.99)38.8 (24.64)28.4 (22.92)41.0 (25.38)−5.7 (18.10)2.5 (17.30)−9.34 (−12.87, −5.81)<0.001Activities of daily livingaA decrease from baseline indicates an improvement32.2 (22.47)33.8 (22.40)26.1 (21.65)33.2 (24.54)−5.9 (18.20)0.3 (18.95)−6.09 (−9.69, −2.49)<0.001Emotional well-beingaA decrease from baseline indicates an improvement22.0 (19.90)27.0 (20.65)17.3 (17.28)26.0 (20.44)−4.8 (17.37)−0.8 (15.30)−5.82 (−8.94, −2.70)<0.001StigmaaA decrease from baseline indicates an improvement20.9 (22.19)24.5 (24.47)15.9 (20.17)23.6 (24.36)−5.1 (18.01)−1.1 (18.17)−5.25 (−8.79, −1.71)0.004Social supportdRopinirole PR n = 167 and placebo n = 157; UPDSR motor 0–108, 0 = normal/no symptoms, UPDRS ADL, 0–52, 0 = normal no symptoms; PDSS, 15 scales, 0 = symptom severe and always experienced to 10 = symptom free, cumulative score for the PDSS is 150 (subject is free of all symptoms); PDQ-39 scale = 0–100 for each domain and ranged from 0 to 100, where 0 represents no problems and 100 represents the number of problems; UPDRS: Unified Parkinson Disease Rating Scale; ADL: Assisted Daily living; HAMD-17: Hamilton Depression rating Scale-17; PDSS:7.6 (15.64)10.0 (16.90)7.1 (14.23)9.4 (17.13)−0.4 (14.63)−0.7 (15.21)−0.96 (−3.81, 1.89)0.507Cognitive impairment30.8 (18.45)31.4 (19.72)29.9 (17.40)31.0 (20.29)−1.1 (14.36)−0.8 (13.28)−0.48 (−3.23, 2.27)0.731CommunicationsaA decrease from baseline indicates an improvement16.8 (17.29)19.0 (20.93)15.8 (17.66)21.7 (21.44)−1.1 (12.28)2.6 (17.21)−4.29 (−7.31, −1.27)0.006Bodily discomfortaA decrease from baseline indicates an improvement30.3 (24.24)32.1 (23.29)27.0 (21.36)32.0 (22.47)–3.5 (19.16)0.7 (19.15)4.45 (−8.03, −0.87)0.015CI: confidence interval.a A decrease from baseline indicates an improvementb An increase from baseline indicates an improvement.c Ropinirole PR n = 170 and placebo n = 160.d Ropinirole PR n = 167 and placebo n = 157; UPDSR motor 0–108, 0 = normal/no symptoms, UPDRS ADL, 0–52, 0 = normal no symptoms; PDSS, 15 scales, 0 = symptom severe and always experienced to 10 = symptom free, cumulative score for the PDSS is 150 (subject is free of all symptoms); PDQ-39 scale = 0–100 for each domain and ranged from 0 to 100, where 0 represents no problems and 100 represents the number of problems; UPDRS: Unified Parkinson Disease Rating Scale; ADL: Assisted Daily living; HAMD-17: Hamilton Depression rating Scale-17; PDSS: Open table in a new tab CI: confidence interval. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled studyParkinsonism & Related DisordersVol. 19Issue 11PreviewThe first evaluation of the efficacy and safety of ropinirole prolonged release (PR) as an adjunct to L-dopa in Chinese patients with advanced Parkinson's disease (PD) not optimally controlled with L-dopa. Full-Text PDF
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study

Regina Katzenschlager,Werner Poewe,Olivier Rascol,Claudia Trenkwalder,Günther Deuschl,K Ray Chaudhuri,Tove Henriksen,Teus van Laar,Donna Lockhart,Harry Staines,Andrew Lees

DOI: https://doi.org/10.1016/j.parkreldis.2020.12.024

Abstract:Introduction: The randomized, double-blind phase (DBP) of the TOLEDO study confirmed the efficacy of apomorphine infusion (APO) in reducing OFF time in PD patients with persistent motor fluctuations despite optimized oral/transdermal therapy. Here we report safety and efficacy results including the 52-week open-label phase (OLP). Methods: All patients completing the 12-week DBP (including those switching early to open-label treatment) were offered OLP entry. The primary objective was the evaluation of long-term safety of APO. Results: Eighty-four patients entered the OLP (40 previously on APO, 44 on placebo) and 59 patients (70.2%) completed the study. The safety profile of APO was consistent with experience from extensive clinical use. Common treatment-related adverse events (AEs) were mild or moderate infusion site nodules, somnolence and nausea. Fourteen (16.7%) patients discontinued the OLP due to AEs, those involving >1 patient were infusion site reactions (n = 4) and fatigue (n = 2); hemolytic anemia occurred in one case. Reduction in daily OFF time and improvement in ON time without troublesome dyskinesia were sustained for up to 64 weeks. Pooled data for week 64 (n = 55) showed a mean (SD) change from DBP baseline in daily OFF time of -3.66 (2.72) hours and in ON time without troublesome dyskinesia of 3.31 (3.12) hours. Mean (±SD) daily levodopa-equivalent dose decreased from DBP baseline to week 64 by 543 mg (±674) and levodopa dose by 273 mg (±515). Conclusions: The safety and efficacy of APO infusion were demonstrated with long-term use for persistent motor fluctuations, allowing substantial reductions in oral PD medication.
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)

Fabrizio Stocchi,Stefano Marconi

DOI: https://doi.org/10.1097/WNF.0b013e3181de8924

Abstract:Parkinson disease is a progressive movement disorder caused by loss of dopaminergic neurons in the substantia nigra. Of unknown etiology, Parkinson disease is characterized by 4 cardinal symptoms: tremor at rest, bradykinesia, postural instability, and rigidity. The current criterion-standard drug used in the management of parkinsonian symptoms is levodopa (l-dopa). However, long-term l-dopa therapy is associated with the development of motor complications; approximately 50% to 80% of patients will develop motor complications within 5 to 10 years of l-dopa treatment initiation. Motor complications can be divided into motor fluctuations, caused largely through pulsatile dopamine stimulation and low l-dopa concentrations, and dyskinesia, associated more often with peak l-dopa concentrations. Ultimately, the main goal was to provide steady l-dopa concentrations, without peaks and troughs. Empirical investigations using parenteral infusions of l-dopa and highly soluble l-dopa prodrugs have shown that there is benefit in ameliorating the peaks and troughs associated with traditional oral l-dopa formulations. Recently, the development of highly soluble oral l-dopa prodrugs has facilitated rapid, regular, and reliable l-dopa availability. This review evaluates some of the pharmacologic strategies in the management of motor complications in Parkinson disease and therapy optimization, with a focus on the use of CHF 1512 (Sirio), a combination of melevodopa (l-dopa methylester, a highly soluble prodrug of l-dopa) plus carbidopa in an effervescent tablet formulation.
Reduced Plasma Levodopa Fluctuations with More Frequent Administration of a Novel Carbidopa/Levodopa Functionally Scored Tablet

Thomas N. Chase,Ahmad AL‐Sabbagh,Minako Koga,Kathleen Clarence‐Smith

DOI: https://doi.org/10.1002/cpdd.1360

2024-01-05

Clinical Pharmacology in Drug Development

Abstract:Levodopa/carbidopa remains the gold standard for treating Parkinson disease (PD), but chronic pulsatile administration contributes to motor complications. This Phase 1 study used a new immediate‐release (IR) formulation of carbidopa/levodopa 25/100 mg that is functionally scored for easy and precise splitting to evaluate the effects on levodopa plasma variability when smaller doses are taken more frequently. These functionally scored tablets were shown to be bioequivalent to carbidopa/levodopa 25‐/100‐mg IR generic reference tablets. Twenty‐two healthy volunteers received a whole tablet every 4 hours versus half of the tablet every 2 hours. Plasma levodopa fluctuations were significantly reduced with half‐tablets dosed every 2 hours, with a 44% reduction in peaks (P < .0001). While drug exposure did not differ, parameters that underlie motor response variations, including mean peak‐to‐trough difference and variance, were 51% and 56% less, respectively, with more frequent dosing (both P ≤ .0024). Safety and tolerability of both regimens were similar. In conclusion, more frequent administration of half‐tablets of the new functionally scored IR formulation safely provided more constant levodopa levels than whole tablets dosed less often. This tablet technology could facilitate the benefits of more physiologic dopamine replenishment in patients with PD, particularly those with reduced manual dexterity.

pharmacology & pharmacy
The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.

Zhenxin Zhang,Jian Wang,Xiaoying Zhang,Shengdi Chen,Zhenfu Wang,Baorong Zhang,Chunfeng Liu,Qiumin Qu,Yan Cheng,Jie Li,Haijun Cao,Meng Cai,Rongxuan Zhu

DOI: https://doi.org/10.1016/j.parkreldis.2013.07.009

IF: 4.402

2013-01-01

Parkinsonism & Related Disorders

Abstract:The first evaluation of the efficacy and safety of ropinirole prolonged release (PR) as an adjunct to L-dopa in Chinese patients with advanced Parkinson's disease (PD) not optimally controlled with L-dopa.In a 24-week, double-blind, placebo-controlled, parallel-group study, subjects with advanced PD were randomized 1:1 to ropinirole PR (N = 175) or placebo (N = 170) as add-on therapy to L-dopa. Primary outcome measure was change from baseline in awake time spent "off". Starting dose of ropinirole PR was 2 mg/day, titrated based on clinical response (maximum 24 mg/day).At week 24, the mean dose of ropinirole PR was 11.4 mg/day with a mean reduction of L-dopa from 506.6 to 411.6 mg/day. Subjects receiving ropinirole PR experienced a significant reduction of "off" time (2.1 h) compared with placebo (0.4 h). Secondary outcome measures including hours of "on" time without troublesome dyskinesis were significantly increased in the ropinirole PR group (1.7 h) compared with placebo (0.3 h). Subjects classified as responders were significantly more frequent in the ropinirole PR (22.8%) than placebo group (2.5%). Efficacy outcomes including Unified Parkinson's disease Rating Scale and PDQ-39 subscales of mobility were significantly improved in the ropinirole PR versus placebo group. The most frequent adverse event experienced in the ropinirole PR group was dyskinesia.This study demonstrated for the first time in Chinese subjects that ropinirole PR improved Parkinson's disease symptoms, permitting a reduction in L-dopa dose. The adverse events observed were consistent with the established safety profile of ropinirole, with no new safety signal identified.
An Open-Label Extension Study to Evaluate the Safety of Ropinirole Prolonged Release in Chinese Patients with Advanced Parkinson’s Disease

Zhenxin Zhang,Jian Wang,Xiaoying Zhang,Shengdi Chen,Zhenfu Wang,Baorong Zhang,Chunfeng Liu,Qiumin Qu,Yan Cheng,Rongxuan Zhu,Jie Li,Jingqiu Hu,Meng Cai

DOI: https://doi.org/10.1185/03007995.2015.1005835

2015-01-01

Current Medical Research and Opinion

Abstract:Objective:This open-label extension (OLE) study evaluated the safety profile of ropinirole prolonged release (PR) administered for 24 weeks as adjunctive to levodopa in Chinese patients with advanced Parkinson's disease (PD).Methods:This was a 24 week, flexible-dose, OLE study in Chinese patients with advanced PD who received 24 week treatment with ropinirole PR in the preceding double-blind (DB), phase III study (NCT01154166) and had no break in receiving study treatment while switching from the DB study to the OLE study. In the OLE study, patients received ropinirole PR once daily, starting with 2 mg/d and increasing up to 8 mg/d at week 4 (2mg increment/week); if tolerable, the dose could be further increased in 4mg increments up to 24 mg/d according to clinical judgment. There were no efficacy assessments. Safety assessments included monitoring adverse events (AEs), neurological examination, Gambling Symptom Assessment Scale questionnaire, liver chemistry, and laboratory tests.Results:Of the 295 enrolled patients, 282 completed the study. The most common reason for withdrawal was AEs (n = 9, 3.1%). The mean duration to ropinirole PR treatment was 173.1 days and an overall median daily dose of ropinirole was 8mg (range: 2-24 mg). Overall, 114 (38.6%) patients experienced on-treatment AEs; the most frequent reported AEs (>= 2%) were dyskinesia (6.1%), dizziness (4.1%), nausea (3.4%), hallucinations (3.4%), somnolence (2.7%) and decreased weight (2.4%). Sixty-eight patients (23.1%) experienced treatment-related AEs. Six patients experienced serious AEs (SAEs), of which hallucination was determined to be a treatment-related SAE. There were no other significant safety findings. No new safety signals for ropinirole were identified.Conclusion:The safety profile of ropinirole was consistent with the preceding DB study and also with the established safety profile for ropinirole. Results support the long-term use of ropinirole PR as an adjunctive to levodopa in Chinese patients with advanced PD.
Radiation-induced cerebral aneurysms

D. Scodary,J. Tew,G. Thomas,T. Tomsick,B. Liwnicz

DOI: https://doi.org/10.1007/BF01405429

Acta Neurochirurgica

Abstract:
Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease

Meir Kestenbaum,Stanley Fahn

DOI: https://doi.org/10.1517/14740338.2015.1015986

2015-02-19

Expert Opinion on Drug Safety

Abstract:INTRODUCTION: Levodopa (LD) is the most effective treatment for Parkinson's disease (PD). However, chronic use of LD commonly results in the development of motor complications, including wearing off and dyskinesia. The presumption that the short serum half-life of LD is associated with the development of motor complications has raised the need to develop treatments with increased durations of stable LD concentrations.AREAS COVERED: We conducted a PubMed search for IPX066 articles and also reviewed abstracts from meetings that included this topic. IPX066 is a newly developed formulation of extended release carbidopa-LD (CD-LD) with a one to four ratio of CD to LD, that was approved by the FDA in January 2015 for the treatment of PD, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide or manganese intoxication. It will be marketed by the trade name Rytary®. A Phase III clinical trial showed that IPX066 is efficacious in improving motor symptoms in early PD patients. In advanced PD patients with motor fluctuations, IPX066 reduced off time and increased on time without troublesome dyskinesia compared to CD-LD immediate release and CD-LD with entacapone. IPX066 had an acceptable safety profile. Adverse events of IPX066 from the different trials are presented.EXPERT OPINION: IPX066 will probably have a role in the treatment of advanced PD with motor fluctuations. IPX066 could also be used initially when LD therapy is prescribed, but the question of whether this usage could reduce or prevent the development of motor complications is yet to be answered.

pharmacology & pharmacy
Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results

F. Stocchi,L. Vacca,M. F. De Pandis,L. Barbato,M. Valente,S. Ruggieri

DOI: https://doi.org/10.1007/s100720170062

2001-02-01

Neurological Sciences

Abstract:Abstract Fluctuations in motor disability and dyskinesias are the major problem in the long-term treatment of Parkinson's disease (PD). Many authors and ourselves have shown that by giving patients a continuous infusion of levodopa it is possible to control motor fluctuations. Levodopa can be administered continuously only be intravenous, intragastric or intrajejunal delivery. Continuous dopaminergic stimulation an be achieved more easily by infusing dopamine agonists subcutaneously. Apomorphine is a potent water-soluble dopamine receptor agonist that has been shown to successfully control motor fluctuation when subcutaneously infused in complicated parkinsonian patients. We report the clinical data of 30 PD patients having at least five years of treatment with subcutaneous continuous apomorphine infusion.

neurosciences,clinical neurology
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Fred Lublin,David H Miller,Mark S Freedman,Bruce A C Cree,Jerry S Wolinsky,Howard Weiner,Catherine Lubetzki,Hans-Peter Hartung,Xavier Montalban,Bernard M J Uitdehaag,Martin Merschhemke,Bingbing Li,Norman Putzki,Fonda C Liu,Dieter A Häring,Ludwig Kappos,INFORMS study investigators

DOI: https://doi.org/10.1016/s0140-6736(15)01314-8

IF: 202.731

2016-03-01

The Lancet

Abstract:BACKGROUND: No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis, but has not been assessed in primary progressive multiple sclerosis. We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis.METHODS: In INFORMS, a multicentre, double-blind, placebo-controlled parallel-group study, patients with primary progressive multiple sclerosis recruited across 148 centres in 18 countries were randomly allocated (1:1) with computer-generated blocks to receive oral fingolimod or placebo for at least 36 months and a maximum of 5 years. Patients were initially assigned to fingolimod 1·25 mg per day or placebo (cohort 1); however, after a protocol amendment on Nov 19, 2009, patients were switched in a masked manner to fingolimod 0·5 mg, whereas those on placebo continued on matching placebo. From then onwards, patients were assigned to receive fingolimod 0·5 mg/day or placebo (cohort 2). Key inclusion criteria were age 25-65 years, clinical diagnosis of primary progressive multiple sclerosis, 1 year or more of disease progression, and two of the following criteria: positive brain MRI; positive spinal cord MRI; or positive cerebrospinal fluid. Additional eligibility criteria included disease duration of 2-10 years and objective evidence of disability progression in the previous 2 years. Patients and study investigators were masked to group assignment. We used a novel primary composite endpoint based on change from baseline in Expanded Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to assess time to 3-month confirmed disability progression in study participants treated for at least 3 years. All randomised patients took at least one dose of study drug. The primary efficacy analysis included all patients in cohort 2 and those assigned to placebo in cohort 1. The safety analysis included all patients in cohorts 1 and 2. This study is registered with ClinicalTrials.gov, number NCT00731692. The study is now closed.FINDINGS: 970 patients were randomly assigned between Sept 3, 2008, and Aug 30, 2011 (147 to fingolimod 1·25 mg and 133 to placebo in cohort 1; 336 to fingolimod 0·5 mg and 354 to placebo in cohort 2). The efficacy analysis set (n=823) consisted of 336 patients randomly allocated to fingolimod 0·5 mg and 487 to placebo. Baseline characteristics were similar across groups and representative of a primary progressive multiple sclerosis population (48% women, mean age 48·5 years [SD 8·4], mean EDSS 4·67 [SD 1·03], 87% free of gadolinium-enhancing lesions). By end of study, 3-month confirmed disability progression had occurred in 232 and 338 patients in the fingolimod and placebo groups, respectively, resulting in Kaplan-Meier estimates of 77·2% (95% CI 71·87-82·51) of patients in the fingolimod group versus 80·3% (73·31-87·25) of patients in the placebo group (risk reduction 5·05%; hazard ratio 0·95, 95% CI 0·80-1·12; p=0·544). Safety results were generally consistent with those of studies of fingolimod in patients with relapse-onset multiple sclerosis. Lymphopenia occurred in 19 (6%) patients in the fingolimod group versus none in the placebo group, bradycardia in five (1%) versus one (<1%), and first-degree atrioventricular block in three (1%) versus six (1%). Serious adverse events occurred in 84 (25%) patients in the fingolimod group and 117 (24%) in the placebo group, including macular oedema in six (2%) versus six (1%), and basal-cell carcinoma in 14 (4%) versus nine (2%).INTERPRETATION: The anti-inflammatory effects of fingolimod did not slow disease progression in primary progressive multiple sclerosis. Therapeutic strategies for primary progressive multiple sclerosis might need different approaches to those used for relapse-onset multiple sclerosis.FUNDING: Novartis Pharma AG.

medicine, general & internal
Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review

Suman Gaire,Sunam Kafle,Sanjiv Bastakoti,Anuj Paudel,Kumar Karki

DOI: https://doi.org/10.7759/cureus.17949

2021-09-13

Cureus

Abstract:Parkinson's disease (PD), a neurodegenerative disorder, is caused due to the loss of dopaminergic neurons in substantia nigra pars compacta, and it mainly affects the motor function of the diseased individual. The most effective treatment for PD to date is levodopa, the precursor molecule for dopamine which ultimately helps overcome the loss of dopamine in the brain. However, long-term levodopa therapy significantly impairs patients' quality of life by causing various disabling motor and non-motor complications. We conducted this study intending to review the available literature that has compared the efficacy and safety of continuous subcutaneous apomorphine infusion (CSAI) with other available treatment options like deep brain stimulation, intestinal levodopa gel, and oral dopaminergic agents. We searched PubMed, Embase, and Scopus databases using the appropriate search strategy. The studies which compared the safety and efficacy of continuous subcutaneous apomorphine infusion to other available treatment options in advanced Parkinson's disease were included in our study. The bias assessment of the studies was done using Cochrane Risk of Bias 2.0 tool for randomized controlled trials, Risk of Bias In Non-Randomized Studies - of Interventions (ROBINS-I) tool for non-randomized interventional studies, and Joanna Briggs Institute Critical Appraisal tools (JBI) for cohort studies. We included eight articles in our systematic review including a randomized controlled trial. None of the included studies had a high risk of bias. We found that in patients with advanced Parkinson's, CSAI demonstrated definite improvement in off-time duration. CSAI has also been shown to improve various non-motor functions, including neuropsychiatric problems in these patients. CSAI has demonstrated safety and efficacy in patients with advanced Parkinson's disease. However, the decision-making is multifactorial. Hence, further studies are required that directly compare the available treatment options with one another and study their overall effects on patients' quality of life.

English Else
Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis.

Caitlin E. Loprinzi Brauer,M. Motosue,James T. Li,John B. Hagan,M. Bellolio,Sangil Lee,R. Campbell

DOI: https://doi.org/10.1016/j.jaip.2016.06.003

2016-11-01

Abstract:
Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease

Miho Murata,Masahito Mihara,Kazuko Hasegawa,Beomseok Jeon,Chon-Haw Tsai,Noriko Nishikawa,Tomoko Oeda,Masayuki Yokoyama,Weining Z. Robieson,Krai Chatamra,Maurizio F. Facheris,Janet Benesh

DOI: https://doi.org/10.1177/1756286418759315

2018-01-01

Therapeutic Advances in Neurological Disorders

Abstract:OBJECTIVES: Levodopa-carbidopa intestinal gel (LCIG) was developed to reduce motor complications in Parkinson's disease (PD) caused by pulsatile levodopa plasma concentrations following oral levodopa administration. Dyskinesia and 'wearing off' symptoms can vary between Asian and Caucasian patients with PD, thus highlighting the importance of assessing the effectiveness of LCIG in an Asian population. Efficacy and safety of LCIG were previously assessed in a 12-week open-label study; we report the efficacy and safety of at least 52 weeks of LCIG treatment in Japanese, Taiwanese, and Korean patients with advanced PD in the ongoing extension study.METHODS: In this interim analysis of a phase III, open-label, multicenter extension study in Japan, South Korea, and Taiwan [ClinicalTrials.gov identifier: NCT02082249/JapiCTI-142482], the mean change from baseline to final visit in 'off' time, as reported in the PD symptom diary, was normalized to a 16-h waking day. Changes in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index and domains scores were also analyzed. Adverse events (AEs) were recorded.RESULTS: Of the 28 patients enrolled (21 Japanese, 3 Taiwanese, 4 Korean), 27 completed at least 52 total weeks of treatment, and 25 patients were continuing in the study at data cutoff. The mean [standard deviation (SD)] 'off' time was significantly reduced by 4.6 (3.1) h/day (p < 0.001, n = 28). Patients experienced significant improvements in quality of life, as recorded by the mean change from baseline in PDQ-39 summary index (p < 0.001). All patients had at least one AE; three patients (11%) discontinued due to an AE. There were two deaths (sepsis and drowning), both of which the investigator considered unrelated to LCIG treatment.CONCLUSIONS: These data suggest that LCIG treatment is efficacious, safe, and well tolerated in Japanese, Taiwanese, and Korean patients with advanced PD, thus confirming the consistency of LCIG treatment in patients with advanced PD.

clinical neurology
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD)

Andreas W. Wolff,Helen Bidner,Yvonne Remane,Janine Zimmer,Dag Aarsland,Olivier Rascol,Richard K. Wyse,Alexander Hapfelmeier,Paul Lingor

DOI: https://doi.org/10.3389/fnagi.2024.1308577

IF: 4.8

2024-02-15

Frontiers in Aging Neuroscience

Abstract:Background: The Rho-kinase (ROCK) inhibitor Fasudil has shown symptomatic and disease-modifying effects in Parkinson's disease (PD) models in vitro and in vivo . In Japan, Fasudil has been approved for the treatment of subarachnoid haemorrhage since 1995 and shows a favourable safety profile. Objectives/design: To investigate the safety, tolerability, and symptomatic efficacy of ROCK-inhibitor Fasudil in comparison to placebo in a randomized, national, multicenter, double-blind phase IIa study in patients with PD. Methods/analysis: We plan to include 75 patients with at least 'probable' PD (MDS criteria), Hoehn and Yahr stages 1–3, and age 30–80 years in 13 German study sites. Patients must be non-fluctuating and their response to PD medication must have been stable for 6 weeks. Patients will be randomly allocated to treatment with the oral investigational medicinal product (IMP) containing either Fasudil in two dosages, or placebo, for a total of 22 days. As primary analysis, non-inferiority of low/high dose of Fasudil on the combined endpoint consisting of occurrence of intolerance and/or treatment-related serious adverse events (SAEs) over 22 days will be assessed in a sequential order, starting with the lower dose. Secondary endpoints will include tolerability alone over 22 days and occurrence of treatment-related SAEs (SARs) over 22 and 50 days and will be compared on group level. Additional secondary endpoints include efficacy on motor and non-motor symptoms, measured on established scales, and will be assessed at several timepoints. Biomaterial will be collected to determine pharmacokinetics of Fasudil and its active metabolite, and to evaluate biomarkers of neurodegeneration. Ethics/registration/discussion: After positive evaluation by the competent authority and the ethics committee, patient recruitment started in the 3rd quarter of 2023. ROCK-PD is registered with Eudra-CT (2021-003879-34) and clinicaltrials.gov (NCT05931575). Results of this trial can pave way for conducting extended-duration studies assessing both symptomatic efficacy and disease-modifying properties of Fasudil.

neurosciences,geriatrics & gerontology,gerontology

Cutaneous Oncology and Immunomodulator Therapy : From Warts to Skin Cancers

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

Subcutaneous Levodopa: A New Engine for the Vintage Molecule

Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

DFT description of the magnetic properties and electron localization in dinuclear di-mu-oxo-bridged manganese complexes.

Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease

Corrigendum to “the Efficacy and Safety of Ropinirole Prolonged Release Tablets As Adjunctive Therapy in Chinese Subjects with Advanced Parkinson’s Disease: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study” [parkinsonism and Related Disorders 19 (2013) 1022–1026]

Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study

Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)

Reduced Plasma Levodopa Fluctuations with More Frequent Administration of a Novel Carbidopa/Levodopa Functionally Scored Tablet

The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.

An Open-Label Extension Study to Evaluate the Safety of Ropinirole Prolonged Release in Chinese Patients with Advanced Parkinson’s Disease

Radiation-induced cerebral aneurysms

Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease

Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review

Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis.

Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD)